Arm A (N=21) | Arm B (N=7) | Arm C (N=17) | Overall (N=45) | |
---|---|---|---|---|
Epertinib + T | Epertinib + T + V | Epertinib + T + C | ||
Sex | ||||
Female | 21 (100%) | 6 (85.7%) | 17 (100%) | 44 (97.8%) |
Male | 0 | 1 (14.3%) | 0 | 1 (2.2%) |
Age (years) | ||||
Mean (range) | 57.6 (38-79) | 49.0 (36-57) | 56.8 (36-75) | 56.0 (36-79) |
ECOG PS at screening | ||||
0 | 11 (52.4%) | 6 (85.7%) | 11 (64.7%) | 28 (62.2%) |
1 | 10 (47.6%) | 1 (14.3%) | 6 (35.3%) | 17 (37.8%) |
Number of metastatic sites at screening | ||||
1-3 | 7 (33.3%) | 4 (57.1%) | 5 (29.4%) | 16 (35.6%) |
≥4 | 14 (66.7%) | 3 (42.9%) | 12 (70.6%) | 29 (64.4%) |
Number of prior anti-cancer therapy regimens | ||||
1-3 | 0 | 1 (14.3%) | 6 (35.3%) | 7 (15.6%) |
≥4 | 21 (100%) | 6 (85.7%) | 11 (64.7%) | 38 (84.4%) |
Prior HER2-targeted therapy | ||||
Trastuzumab | 21 (100%) | 7 (100%) | 17 (100%) | 45 (100%) |
T-DM1 | 15 (71.4%) | 3 (42.9%) | 13 (76.5%) | 31 (68.9%) |
Lapatinib | 10 (47.6%) | 2 (28.6%) | 7 (41.2%) | 19 (42.2%) |
Pertuzumab | 3 (14.3%) | 2 (28.6%) | 4 (23.5%) | 9 (20.0%) |
Prior Capecitabine / Vinorelbine | ||||
Capecitabine | 16 (76.2%) | 4 (57.1%) | 11 (64.7%) | 31 (68.9%) |
Vinorelbine | 9 (42.9%) | 1 (14.3%) | 10 (58.8%) | 20 (44.4%) |